The agenda item on next-generation sequencing at the recent J.P. Morgan Healthcare conference was highly appropriate given the spate of activities that took place in that field leading up to and during the event. On the opening day, for example, big pharma Roche AG, of Basel, Switzerland, revealed it was acquiring a majority ownership in Foundation Medicine Inc. (FMI) in a transaction valued at up to $1.05 billion.